


AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An immunological test kit comprising one or more immunologically reactive substances connected to an immunologically invisible carrier, said immunologically invisible carrier comprising polyethylene glycol copolymer units of the structure of:



wherein n represents the number of units connected in a chain, and R represents an attachment site for the one or more immunologically reactive substances.

2. (Original) The test kit of claim 1, wherein said immunological test kit is an ELISA kit.
3. (Original) The test kit of claim 1, wherein said immunological test kit is an immuno-capillary kit.
4. (Cancelled)
5. (Previously Presented) The test kit of claim 1 wherein the one or more immunologically reactive substances comprise an epitope.
6. (Previously Presented) The test kit of claim 1 wherein the one or more immunologically reactive substances comprise an antibody.

7. (Previously Presented) The test kit of claim 1, wherein the one or more immunologically reactive substances comprises an antigen.

8. (Cancelled)

9. (Previously Presented) The test kit of claim 1, wherein the carrier consists of two to two hundred units.

10. (Previously Presented) The test kit of claim 1, wherein the carrier consists of four to twenty units.

11. (Previously Presented) The test kit of claim 5, wherein the one or more immunologically reactive substances comprise two distinct epitopes.

12. (Previously Presented) The test kit of claim 5, wherein a unit carries more than one epitope.

13. (Currently Amended) The test kit of claim 1, wherein the one or more immunologically reactive substances comprise an amino acid sequence selected from the group consisting of:

VQEGVQQEGAQQP-(beta-A)(beta-[[,4]]A)C; EIAAKAIGKKIHQNNG-(beta-A)(beta-A)C;
ISTLIKQKLDGLKNE-(beta-A)(beta-A)C; PWAESPCKPEPVVAESPCKPE-(beta-A)(beta-A)C;
DKKAINLDKAQQKLD-(beta-A)(beta-A)C; ITKGKSQKSLGD-(beta-A)(beta-A)C; and
GMTFRAQEGAFLTG-(beta-A)(beta-A)C.

14. (Previously Presented) The test kit of claim 1, further comprising a reporter moiety connected to the immunologically invisible carrier, wherein the reporter moiety is attached:

(a) directly to the carrier at position R, if other positions R of the copolymer units are occupied by one or more immunologically reactive substances;

(b) directly to the carrier at a position other than at position R; or

(c) indirectly to the carrier by being attached to the one or more immunologically reactive substances, the substances being directly attached to the carrier.


15. (Previously Presented) The test kit of claim 14, wherein the reporter moiety attachment occurs:

(a) before an immunological assay; or

(b) during or after an immunological assay.

16. (Previously Presented) The test kit of claim 14, wherein the reporter moiety is biotin.

17. (Previously Presented) A composition of matter comprising one or more immunologically reactive substances connected to an immunologically invisible carrier, said immunologically invisible carrier comprising polyethylene glycol copolymer units of the structure of:



wherein n represents the number of units connected in a chain, and R represents an attachment site for the one or more immunologically reactive substances.

18. (Previously Presented) The composition of matter of claim 17, wherein the one or more immunologically reactive substances comprise one or more epitopes.

19. (Previously Presented) The composition of matter of claim 18, wherein the carrier consists of two to two hundred units.

20. (Previously Presented) The composition of matter of claim 18, wherein the carrier consists of four to twenty units.

21. (Previously Presented) The composition of matter of claim 18, wherein the one or more epitopes comprise the same epitope.

22. (Previously Presented) The composition of matter of claim 18, wherein the one or more epitopes comprise two distinct epitopes.

23. (Previously Presented) The composition of matter of claim 18, wherein the one or more epitopes comprise three distinct epitopes.

24. (Previously Presented) The composition of matter of claim 18, wherein a unit carries more than one epitope.

25. (Currently Amended) The composition of matter of claim 18, wherein the one or more epitopes comprise an amino acid sequence selected from the group consisting of:

VQEGVQQEGAQQP-(beta-A)(beta-[[,4]]A)C; EIAAKAIGKKIHQNNG-(beta-A)(beta-A)C;
ISTLIKQKLDGLKNE-(beta-A)(beta-A)C; PWAESPCKPEPVVAESPCKPE-(beta-A)(beta-A)C;
DKKAINLDKAQQKLD-(beta-A)(beta-A)C; ITKGKSQKSLGD-(beta-A)(beta-A)C; and
GMTFRAQEGAFLTG-(beta-A)(beta-A)C.

26. (Previously Presented) The composition of matter of claim 18, further comprising a reporter moiety connected to the immunologically invisible carrier, wherein the reporter moiety is attached:

(a) directly to the carrier at position R, if other positions R of the copolymer units are occupied by one or more epitopes;

(b) directly to the carrier at a position other than at position R; or

(c) indirectly to the carrier by being attached to the one or more epitopes, the epitopes being directly attached to the carrier.

27. (Previously Presented) The composition of matter of claim 26, wherein the reporter moiety is biotin.

28. (Previously Presented) The composition of matter of claim 18, wherein the one or more epitopes are attached to a linking molecule, the linking molecule being attached directly to the immunologically invisible carrier.
